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Background: Nephrotoxicity is an important adverse effect of colistin methanesulfonate (CMS) therapy. No data
exist on rates and risk factors for colistin-related nephrotoxicity in Saudi Arabia (SA). We conducted a prospective
cohort study to identify rates and risk factors for CMS nephrotoxicity in our patient population.
Methods: We prospectively included adult patients who received ≥48 hours of intravenous CMS therapy. Pregnant
patients and those on renal replacement were excluded. Patients received 9 million units (mU) loading dose followed
by 3 mU 8 hourly. In renal impairment, CMS dosing was adjusted according to calculated creatinine clearance (CrCl).
Nephrotoxicity was defined as per RIFLE criteria (Risk, Injury, Failure, Loss and End-stage renal disease). Statistical analysis
was performed using SPSS version 20.0 (IBM, Armonk, New York, USA). The study was approved by the institution’s
Research Ethics Committee.
Results: A total of 67 patients were included in the study. Mean (±standard deviation) age was 57.5 (±24.0) years, Charlson
Co-morbidity Score 2.88 (±2.39), CrCl 133.60 (±92.54) mL/min and serum albumin 28.65 (±4.45) g/L. Mean CMS dose was
0.11 (±0.04) mU/kg/day and mean total CMS dose received was 101.21 (±47.37) mU. Fifty-one (76.1%) patients developed
RIFLE-defined nephrotoxicity. Mean total CMS dose and duration of therapy before onset of nephrotoxicity were 66.71
(±43.45) mU and 8.70 (±6.70) days, respectively. In bivariate analysis, patients with nephrotoxicity were significantly older
(P 0.013) and had lower baseline serum albumin (P 0.008). Multivariate logistic regression identified serum albumin [odds
ratio (OR) 0.72; 95% confidence interval (CI) 0.57–0.93; P 0.010] and intensive care admission (OR 16.38; 95% CI 1.37–195.55;
P 0.027) as independent risk factors for CMS nephrotoxicity.
Conclusions: High dose intravenous CMS therapy is associated with high rates of nephrotoxicity in SA. Independent risk
factors for colistin nephrotoxicity were baseline hypoalbuminemia and intensive care admission.
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Table 1 RIFLE Criteria for acute kidney injury
Category Criteria
Risk (R) Increased serum creatinine level by 1.5 times or
GFR decrease by >25%
Injury (I) Increased serum creatinine level by 2.0 times or
GFR decrease by >50%
Failure (F) Increased serum creatinine level by 3.0 times, GFR
decrease by >75% or serum creatinine level
≥354 μmol/L
Loss (L) Persistent acute renal failure or complete loss of
function for >4 weeks
End-stage kidney
disease (E)
End-stage kidney disease for >3 months
GFR = glomerular filtration rate.
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Infections caused by carbapenem-resistant Gram-negative
bacteria are becoming increasing more common, resulting
in a parallel increase in the clinical use of intravenous co-
listin methanesulfonate (CMS), commonly known as co-
listin [1]. Data from pharmacokinetic studies suggest that
standard CMS dosing regimens result in sub-optimal
serum and target organ concentrations [2]. Moreover,
without a high loading dose, it can take over 48 hours for
colistin serum levels to reach steady state [3]. Many cen-
tres have changed their colistin dosing practice in an at-
tempt to optimize antimicrobial treatment for patients
with infections caused by carbapenem-resistant, Gram-
negative bacteria [4].
Amongst the important potential adverse effects of
CMS therapy are nephrotoxicity and neurotoxicity [5]. A
number of risk factors for CMS-associated nephrotoxicity
have been identified in different studies. However, it ap-
pears that CMS-related nephrotoxicity is reversible in the
majority of cases and does not usually result in premature
treatment discontinuation [5]. No data exist on the rates
and risk factors for CMS-associated nephrotoxicity from
Saudi Arabia or the Arabian Peninsula.
In May 2012, we introduced a CMS dosing protocol
utilizing loading doses with higher maintenance doses
for all patients requiring intravenous CMS therapy. The
purpose of this study was to prospectively evaluate
colistin-associated nephrotoxicity rates in our institution
and to explore risk factors in our patient population.
Methods
Design
We conducted a prospective cohort study of adult patients
starting targeted or empiric intravenous CMS therapy over
the period from April 1 to September 30, 2013 in a large
tertiary care centre in Riyadh, Saudi Arabia. The study was
approved by Prince Sultan Military Medical City Research
Ethics Committee and was granted a waiver for informed
consent.
Patients
We included all patients aged 18 years or more who re-
ceived for ≥ 48 hours of intravenous CMS therapy. Exclusion
criteria included current receipt of any form of renal re-
placement therapy, receipt of CMS therapy within the pre-
ceding 7 days, pregnancy, cystic fibrosis and extensive
burns.
Procedures
Baseline creatinine clearance (CrCl) was estimated using
Cockroft-Gault equation [6]. Colistin was administered as
Colomycin (Forest Laboratories, Bextley, United King-
dom), which is supplied in vials of 1 million units (mU) of
CMS, equivalent to 80 mg CMS or 30 mg colistin baseactivity. Patients with normal renal function received
9 mU as a loading dose, followed 24 hours later by 3 mU
every 8 hours. Adjustment in CMS dosing for patients
with renal impairment, defined as estimated CrCl <
60 mL/min, was according to those recommended by Gar-
onzik et al. [7]. We collected baseline demographic and
clinical data including gender, age, body weight, site of in-
fection and Charlson Co-morbidity Index [8]. Renal func-
tion and estimated CrCl were recorded on daily basis
from start of CMS therapy up to 7 days after its discon-
tinuation. Concomitant receipt of loop diuretics, amino-
glycosides, vancomycin, amphotericin b preparations,
non-steroidal anti-inflammatory agents or intravenous
contrast was also recorded. CMS-related nephrotoxicity
was defined according to RIFLE criteria [9] (Table 1).
Outcomes
The primary end-point was the occurrence of RIFLE-
defined nephrotoxicity whilst on intravenous CMS ther-
apy. Secondary end-point was analysis of risk factors for
CMS-associated nephrotoxicity.
Statistical analysis
Bivariate analyses were performed using Fisher exact
tests for categorical variables and the independent sam-
ple t test for continuous variables. Clinically important
variables and those with P values of <0.2 in the bivariate
analysis were included the multivariate logistic analysis.
All P values were 2-sided and were considered signifi-
cant if <0.05. Statistical analysis was performed using
SPSS version 20.0 (IBM, Armonk, New York, USA).
Results and discussion
A total of 95 patients were started on high-dose intraven-
ous CMS therapy during the study period, of which 67
met the inclusion criteria (Figure 1). Mean age (±standard
deviation) was 57.48 (±24.01) years and 45 (67.2%) were
males. Twenty-one patients (31.3%) were in an intensive
care unit (ICU) and the average Charlson Co-morbidity
Score was 2.88 (±2.39). At start of CMS therapy, mean
Patients receiving high-dose 
intravenous CMS therapy during 
study period (n = 95) 
Renal replacement therapy at 
baseline (n = 23) 
Patient aged <18 years (n = 3) 
Intravenous CMS therapy within 
the preceding 7 days (n = 2) 
Patients included in study (n = 67) 
Figure 1 Study population and patient selection. CMS = Colistin
methanesulfonate.
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albumin was 28.65 (±4.45) g/L. Sixteen patients (23.9%)
had renal impairment (estimated CrCl < 60 mL/min) prior
to starting CMS therapy and 29 (43.3%) had history of dia-
betes mellitus. Patients received an average intravenous
CMS dose of 0.11 (±0.04) mU per kilogram per day, for an
average duration of 13.76 (±6.77) days. The mean total
CMS dose received was 101.21 (±47.37) mU. The under-
lying infections included hospital-acquired pneumonia
(36, 53.7%), urinary tract infection (13, 19.4%), bacter-
aemia (7, 10.5%), skin and soft tissue infection (5, 7.5%)
and other infections (6, 9.0%). Other baseline patient char-
acteristics are summarized in Table 2.
A total of 51 (76.1%) patients developed RIFLE-defined
CMS-related nephrotoxicity; 19 (37.3%) R; 20 (38.5%) I;
and 12 (23.5%) F. Only 3 (5.9%) patients required renal re-
placement therapy. There were no treatment discontinua-
tions secondary to nephrotoxicity.
The mean total CMS dose received before onset of
nephrotoxicity was 66.71 (±43.45) mU and the mean
duration of CMS therapy before onset of nephrotoxicity
was 8.70 (±6.70) days. In bivariate analysis, patients who
developed CMS-related nephrotoxicity were significantly
older (P 0.013) and had lower baseline serum albumin
(P 0.008). There were no other statistically significant
differences between the two groups (Table 2). In multi-
variate logistic regression analysis, serum albumin [odds
ratio (OR) 0.72; 95% confidence interval (CI) 0.57–0.93;
P 0.010] and ICU status (OR 16.38; 95% CI 1.37–195.55;
P 0.027) were the only independent risk factors for
CMS-associated nephrotoxicity (Table 2). Renal function
returned to baseline level within 7 days in 19 (37.3%)
out of 51 patients who developed CMS-associated
nephrotoxicity.
The realization that higher doses of CMS are required to
optimize serum colistin concentration has been associated
with concerns over an increased risk of nephrotoxicity. Afew studies had reported the rates and risk factors for CMS-
related nephrotoxicity, but ours is the first from the Arabian
Peninsula region (Table 3) [10-20]. Whereas rates ranging
between 17.8% and 53.5% were previously reported, just
over 3 quarters (76.1%) of 67 adult patients included in our
study developed acute kidney injury (AKI) whilst receiving
high dose intravenous CMS therapy. Even though it has
been suggested that using sensitive criteria such as RIFLE
may result in higher rates of AKI, our rates are relatively
high even when compared with studies that used the same
definitions (Table 3). The reasons for such high rates of
nephrotoxicity in our study are not clear. Baseline character-
istics of our study population are comparable to those from
previous studies and only 31.3% were critically ill. Further-
more, our dosing regimens are similar to some of those re-
ported previously. It is noteworthy that despite the high rate
of AKI in our study, only a small proportion of our patients
(3, 5.9%) required renal replacement therapy and colistin
therapy was not discontinued because of nephrotoxicity in
any of the cases.
Various risk factors for colistin-related nephrotoxicity
were previously reported. However, only older age and
baseline hypoalbuminemia were significantly different in
our patients who developed AKI whilst on intravenous
CMS therapy. There were no other statistically significant
differences in rates of diabetes mellitus, baseline serum
creatinine levels, ICU status, daily or cumulative CMS
dose or duration of CMS therapy (Table 2). Moreover, our
multivariate regression analysis identified lower baseline
serum albumin levels and ICU status as the only inde-
pendent risk factors for colistin-related AKI. Interestingly,
serum albumin was included in 2 previous studies, both of
which reported a significant association in multivariate
analyses [18,20]. It had been suggested that AKI maybe re-
lated to higher free colistin concentrations as a result of
lower protein binding [5,20]. From a clinical perspective,
it would be of interest to investigate whether albumin re-
placement could reduce the risk of colistin-related
nephrotoxicity in patients with lower albumin levels. On
the other hand, ICU status was included in many previous
studies but was not previously reported to have a signifi-
cant independent association with colistin-related nephro-
toxicity [13,15-17]. Contrary to our findings, some authors
hypothesized that improved monitoring in ICU setting
may contribute to lower rates of CMS-associated nephro-
toxicity [5]. Overall, the literature has not been consistent
on which variable are predictive of CMS nephrotoxicity
(Table 3). This is probably due to the heterogeneity of the
studies in terms of severity of illness of included patients,
CMS dosing protocols and even definitions of AKI. For
example, Hartzell et al. [19] included relatively younger
patients with low co-morbidity scores, whereas others in-
cluded only patients from ICU [14] or those with body
mass indices of more than 25 kg/m2 [13].







Bivariate analysis Multivariate logistic regression
P value OR (95% CI) P value
Age (years)a 57.48 (±24.01) 61.53 (±22.44) 44.56 (±24.99) 0.013 0.98 (0.96–1.04) 0.494
Body weight (kg)a 73.67 (±21.33) 72.78 (±18.90) 76.50 (±28.26) 0.547 - -
Male genderb 45 (67.2%) 33(76.1%) 12 (75.0%) 0.55 - -
Charlson Co-morbidity Scorea 2.88 (±2.39) 2.86 (±2.14) 2.94 (±3.15) 0.914 - -
Diabetes mellitusb 29 (43.2%) 25 (49.0%) 4 (25.0%) 0.15 0.52 (0.06–4.87) 0.568
Baseline CrCl (mL/min)a 133.60 (±92.54) 126.02 (±85.57) 157.94 (±111.52) 0.23 0.99 (0.98–4.87) 0.108
Baseline serum albumin (mg/L)a 28.65 (±4.45) 27.86 (±4.19) 31.19 (±4.48) 0.008 0.72 (0.57–0.93) 0.010
Intensive care unit careb 21 (31.3%) 13 (25.5%) 8 (50.0%) 0.12 16.38 (1.37–195.55) 0.027
Receipt of CMS Loading dose 52 (77.6%) 39 (76.5%) 13 (81.3%) 1.0 - -
CMS Dose (mU/kg/day)a 0.11 (±0.04) 0.11 (±0.04) 0.10 (±0.04) 0.48 - -
Cumulative CMS dose (mU)a 101.21 (±47.37) 106.47 (±45.91 84.44 (±49.56) 0.105 1.00 (1.00–1.00) 0.133
Duration of CMS therapy (days)a 13.76 (±6.77) 14.16 (±5.54) 12.50 (±9.86) 0.397 0.96 (0.83–1.11) 0.555
Number of concomitant nephrotoxic agentsa 0.71 (±0.62) 0.76 (±0.65) 0.56 (±0.51) 0.26 2.37 (0.50–11.19) 0.277
Concomitant vancomycin therapyb 33 (49.3%) 24 (47.1%) 9 (56.3%) 0.576 - -
Concomitant furosemide therapyb 11 (16.4%) 8 (15.7%) 3 (18.75%) 0.715 - -
Concomitant aminoglycoside therapyb 3 (4.47%) 2 (3.92%) 1 (6.25%) 0.559 - -
Concomitant NSAIDb 2 (2.98%) 2 (3.92%) 0 (0.0%) 1.00 - -
Concomitant radiological contrastb 1 (1.49%) 1 (1.96%) 0 (0.0%) 1.00 - -
Concomitant amphotericin b therapyb 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.00 - -
CrCl = creatinine clearance; CMS = colistin methanesulfonate; OR = odds ratio; NSAID = Non-steroidal anti-inflammatory drugs.

























defined as per RIFLE criteria?
Rate of
nephrotoxicity
Independent risk factors for CMS-associated nephrotoxicity
Balkan et al., 2014 [10] Retrospective cohort, 198
patients
Turkey Yes 46.1% Age > 60 years
Sorli et al., 2013 [11] Prospective cohort; 102
patients
Spain Yes 49.0% Trough serum colistin level, Charlson Score and receipt of≥ 2 concomitant
nephrotoxic agents.
Dalfino et al., 2012 [12] Prospective cohort; 28 ICU
patients
Italy No 17.8% Receipt of radio-contrast.
Gauthier et al., 2012 [13] Case–control; 370 patients
with BMI > 25 kg/m2
United States Yes 48% BMI≥ 31.5 kg/m2, diabetes mellitus, older age and length of hospital stay.
Doshi et al., 2011 [14] Retrospective cohort; 49 ICU
patients
United States Yes 31% Pre-existing chronic kidney disease, systemic hypertension, receipt of
radio-contrast and receipt of≥ 2 concomitant nephrotoxic agents.
Pogue et al., 2011 [15] Retrospective cohort; 126
patients






Thailand No 52.5% Older age, longer duration of CMS therapy, higher CMS doses and
concomitant vancomycin therapy.
Deryke et al., 2010 [17] Retrospective cohort; 30
patients
United States Yes 33% Dosing based on actual body weight.
Kwon et al., 2010 [18] Retrospective cohort; 71
patients
South Korea Yes 53.5% Male gender, concomitant use of a calcineurin inhibitor, hypoalbuminaemia
and hyperbilirubinaemia.
Hartzell et al., 2009 [19] Retrospective cohort; 66
patients
United States Yes 45% Cumulative CMS dose and longer duration of therapy.
Kim et al., 2009 [20] Case–control; 47 cases South Korea Yes 31.9% Hypoalbuminemia and concomitant use of non-steroidal anti-inflammatory
drugs.
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the lack of a control group to better assess the effect of vari-
ous variables. Moreover, it would have useful to include
pharmacokinetic assessment to investigate the relationship
between serum colistin levels and rates of nephrotoxicity. Fi-
nally, we noted that renal function recovered to baseline
levels in over one third (37.3%) of patients with CMS-
associated nephrotoxicity. Extending follow up to a period
of 3 to 6 months could have helped understand the medium
to long-term prognosis.
Conclusions
High-dose intravenous CMS therapy is associated with high
rates of nephrotoxicity in Saudi Arabia. The main independ-
ent risk factors in our patient population are low serum al-
bumin at baseline and ICU status. Adequately controlled
studies of appropriate size are required to better understand
the factors associated with CMS-nephrotoxicity and identify
potentially useful intervention to prevent its occurrence.
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